Phibro Animal Health news

PAHC has a superior Zacks Rank #2 (Buy) indicating positive earnings estimate revisions, a strong Value grade of A, lower forward P/E ratio (10.06 vs 20.36), lower PEG ratio (1.02 vs 2.15), and lower P/B ratio (3.62 vs 5.84), making it the more attractive value opportunity.

Zacks Rank #2, VGM Score A, 18.4% trailing four-quarter earnings surprise (highest among the four), strong interest coverage ratio, though modest 6.5% EPS growth expected and 9.2% stock decline over past year

PAHC has a stronger Zacks Rank (#2 Buy vs #4 Sell), superior Value grade (A vs D), lower forward P/E ratio (11.20 vs 28.10), and lower PEG ratio (1.13 vs 2.34), indicating better earnings outlook and undervaluation relative to growth prospects.

While the company showed solid revenue growth of 4.8% YoY and exceeded expectations in Latin America/Canada region (+26.37% surprise), it received a Zacks Rank #3 (Hold) rating, indicating expected performance in line with the broader market. Recent monthly stock performance (1.6%) lagged the S&P 500 (2.7%), though three-month performance was stronger at 18.8%. The neutral sentiment reflects mixed near-term outlook despite solid fundamentals.

The insider sale is presented as a routine, pre-scheduled transaction tied to a planned CEO transition rather than a bearish signal. Bendheim maintains substantial ownership (73,000+ shares), and the article emphasizes that investor focus should be on the new CEO's execution of recent acquisitions and margin expansion rather than this filing.

Holds Zacks Rank #1 with modest but consistent growth expectations (3.8% sales, 8.7% earnings) and a solid trailing four-quarter earnings surprise average of 18.4%.

Phibro Animal Health holds a Zacks Rank #1 (Strong Buy) with an exceptional earnings yield of 10.2% and consistent earnings beats averaging 18.4% surprise, despite recent stock underperformance.